BAR502, is a dual FXR and GPBAR1 agonist32–34, that is currently advanced to clinical stage, that was shown effective in reducing steatosis and fibrosis in rodents model of NAFLD and NASH. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.